Regeneron Slashes Praluent Price 58% and Offers Free Otarmeni Therapy
Regeneron cut Praluent’s price by 58% to $225 via the US Most Favored Nation scheme and will apply MFN pricing to all new therapies. It will supply Otarmeni gene therapy for OTOF-linked hearing loss free to eligible US patients after 80% of trial participants improved, and invest $27 billion in US R&D and manufacturing by 2029.
1. Pricing Deal Under MFN Scheme
Regeneron agreed to the US Most Favored Nation scheme, reducing Praluent’s list price by 58% from $537 to $225 for patients using the TrumpRx.gov platform and extending MFN pricing to all future therapies.
2. Free Otarmeni Gene Therapy Rollout
The FDA approved Otarmeni on April 23 under the CNPV program for patients with OTOF gene-linked hearing loss, with Phase I/II trial results showing 80% of participants experienced hearing improvements at 24 weeks. The therapy will be offered at no cost to eligible US patients.
3. $27 Billion US R&D and Manufacturing Investment
Regeneron committed $27 billion to expand US R&D and manufacturing capacity by 2029, aiming to more than double its domestic production footprint and support scaling of its pipeline.